A method and system are described for continuously assessing the quality of field data in a clinical study, identifying clinical sites with weaker performance than other sites, and flexibly allocating resources to address the problems, including the need to send field monitors to a site. The sites are compared with respect to the number of database entries requiring verification, and a higher priority (for allocation of management resources) is given to sites that have generated higher numbers of unverified database entries. The invention is particularly useful in the conduct of adaptive clinical trials of pharmaceutical products.
展开▼